TFE3 (MRQ-37) Rabbit Monoclonal Antibody
SIGMA/354R-1
Product Type: Chemical
Immunohistochemistry TFE3 (MRQ-37) on renal cell carcinoma
| antibody form | culture supernatant |
| antibody product type | primary antibodies |
| biological source | rabbit |
| clone | MRQ-37, monoclonal |
| conjugate | unconjugated |
| control | ASPS, melanoma |
| description | For In Vitro Diagnostic Use in Select Regions (See Chart) |
| form | buffered aqueous solution |
| isotype | IgG |
| manufacturer/tradename | Cell Marque® |
| packaging | bottle of 1.0 mL predilute (354R-17) |
| bottle of 7.0 mL predilute (354R-18) | |
| vial of 0.1 mL concentrate (354R-14) | |
| vial of 0.5 mL concentrate (354R-15) | |
| vial of 1.0 mL concentrate (354R-16) | |
| Quality Level | 100  |
| 500 |
|
| shipped in | wet ice |
| species reactivity | human |
| storage temp. | 2-8°C |
| technique(s) | immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:50-1:200 |
| visualization | nuclear |
| Analysis Note: |
|
||||
| General description: | Xp11 translocation renal cell carcinomas (RCC) are a recently recognized subset of RCC, characterized by chromosome translocations involving the Xp11.2 break point and resulting in gene fusions involving the TFE3 transcription factor gene that maps to this locus. Xp11 translocation RCC represents the most common type of RCC in children, but is less frequent on a percentage basis in adults. Morphologically, these neoplasms frequently show papillary architecture and clear cytoplasm, and frequently have associated psammoma bodies. Immunohistochemically, these neoplasms under-expresses epithelial markers such as anti-cytokeratin and anti-epithelial membrane antigen (anti-EMA) compared with typical adult type RCC. The most sensitive and specific immunohistochemical marker for the Xp11 translocation RCC is nuclear labeling of TFE3 protein, which reflects over-expression of the resulting fusion proteins relative to native TFE3. Alveolar soft part sarcoma (ASPS) is an uncommon soft tissue sarcoma of undertain differentiation. It presents in younger patients, often in the extremities. Despite relatively high rates of metastasis, patients often experience prolonged survival in the metastatic setting relative to others. The hallmark of ASPS is a chromosomal rearrangement at 17q25 and Xp11.2 engendering an ASPSCR1-TFE3 fusion gene responsible for an aberrant transcription factor presumably enabling pathogenesis.This aberrant chimeric transcription factor retains the N-terminal DNA binding domain encoded by TFE3 while the ASPSCR1 encoded portion probably provides domain(s) modulating gene expression. The presence of this ′super-activated′ transcription factor may induce the expression of numerous molecules contributing to ASPS diagnosis, progression, and metastasis. | ||||
| Legal Information: | Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany | ||||
| Other Notes: | For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com | ||||
| Other Notes: | TFE3 Positive Control Slides, Product No. 354S , are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections). |
||||
| Physical form: | Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide | ||||
| Preparation Note: | Download the IFU specific to your product lot and format  Note: This requires a keycode which can be found on your packaging or product label. |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 2 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352203 |